News Archive

22 August 2013

MSD Animal Health Introduces Innovative Program to Improve Poultry Respiratory Health

The Convenience Program – Improving Birds Breathing from the Beginning 

NANTES, FRANCE 22 August 2013 – MSD Animal Health (known as Merck Animal Health in the USA and Canada) today announced that it is introducing an innovative and unique advancement – the Convenience Program – that will help the poultry industry control respiratory diseases starting at the hatchery, improving their vaccination process and performance enhancement. The official launch occurred at the XVIIIth Congress of the World Veterinary Poultry Association, 19 – 20 August, in Nantes, France.

The Convenience Program is designed to meet the farmers’ current and future needs for process improvement and performance enhancement.

“Today, more than 70% of the broilers produced worldwide reach their targeted weight of 2.5 Kg at 42 days of age and the growth curve is speeding due to continuous genetic evolution, better feed formulation and stronger health conditions, said Laura Villarreal, MSD Global Marketing Director. “It is estimated that by 2020, the same number of broilers will reach that weight in 35 days, a full week less. This shortened growth cycle will reduce the time available for field vaccinations and mean there is no more time for vaccine failures and reactions.”

The Convenience Program starts in the hatchery; with choosing the right combinations of vaccines and the most favorable route of application. Together these factors reduce stress and improve the birds’ breathing from the beginning. “Conventional respiratory vaccines themselves may reduce flock performance due to reactions or cause incomplete protection and insufficient duration of immunity,” said Dr Rik Koopman, MSD Global Technical Director.

The method of vaccine timing introduced through the Convenience Program is to combine in-ovo and day-old vaccination application. This provides earlier and longer protection. MSD Animal Health has developed an effective range of vaccines with biological behaviors that allows them to be combined, without losing efficacy, and without producing adverse reactions.

To help implement the Convenience Program, MSD Animal Health will provide extensive support to ensure it delivers maximum impact on flock performance both in terms of flock health and cost savings. Respiratory disease protection is more than convenience; it is about efficacy and superior performance. With the Convenience Program, respiratory protection begins in the hatchery and so do the benefits.

About MSD Animal Health
Today's Merck is a global healthcare leader working to help the world be well. MSD Animal Health, known as Merck Animal Health in the United States and Canada, is the global animal health business unit of Merck. MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com.

Merck forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2012 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).